strategy and plans; corporate strategy update; pipeline potential and progress; potential of our commercial business and pipeline programs; the prospects of our product portfolio; capital allocation and investment strategy; clinical development programs, clinical trials and data readouts and presentations; regulatory �lings and the timing thereof; risks and uncertainties associated with drug development and commercialization; the potential bene�ts, safety and ef�cacy of our products and investigational therapies; anticipated bene�ts and potential of investments, collaborations and business development activities; our future �nancial and operating results; and the potential impact of the COVID- business and operations.